US 12,270,033 B2
Dual leucine zipper kinase inhibitors for gene therapy
Thomas W. Chalberg, Jr., Redwood City, CA (US)
Assigned to Exhaura, Ltd., Palo Alto, CA (US)
Appl. No. 17/430,269
Filed by Exhaura, Ltd., Palo Alto, CA (US); and Thomas W. Chalberg, Jr., Redwood City, CA (US)
PCT Filed Feb. 13, 2020, PCT No. PCT/US2020/018161
§ 371(c)(1), (2) Date Aug. 11, 2021,
PCT Pub. No. WO2020/168111, PCT Pub. Date Aug. 20, 2020.
Claims priority of provisional application 62/806,213, filed on Feb. 15, 2019.
Claims priority of provisional application 62/806,210, filed on Feb. 15, 2019.
Prior Publication US 2022/0213494 A1, Jul. 7, 2022
Int. Cl. C12N 9/12 (2006.01); C12N 15/79 (2006.01)
CPC C12N 15/79 (2013.01) [C12N 9/12 (2013.01); C12N 2750/14143 (2013.01); C12Y 207/11025 (2013.01)] 16 Claims
OG exemplary drawing
 
1. An inhibitor, comprising a protein comprising a leucine zipper domain that shares at least 95% identity to SEQ ID NO: 1, wherein the leucine zipper domain comprises at least one substitution at one or more of the positions 391 and 393.